Dual Role for Inflammasome Sensors NLRP1 and NLRP3 in Murine Resistance to Toxoplasma gondii

Gezahgn Gorfu,a**, Kimberly M. Cirelli, b Mariane B. Melo, b Katrin Mayer-Barber, c Devorah Crown, d Beverly H. Koller, e,f Seth Masters, g Alan Sher, f Stephen H. Leppla, h Mahtab Moayeri, i Jeroen P. J. Saeij, b Michael E. Grigg a

Molecular Parasitology Section, Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, Maryland, USA; a; Immunobiology Section, Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, Maryland, USA; a; Microbial Pathogenesis Section, Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, Maryland, USA; a; Pulmonary Division, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA; a; Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA; a; Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

**Present address: Gezahgn Gorfu, Howard University, Washington, DC, USA.

ABSTRACT Induction of immunity that limits Toxoplasma gondii infection in mice is critically dependent on the activation of the innate immune response. In this study, we investigated the role of cytoplasmic nucleotide-binding domain and leucine-rich repeat-containing (NLR) proteins detect the presence of pathogen is critically dependent on monocyte and macrophage cell activation. Hence, induction of protective immunity against this protozoan pathogen is critically dependent on monocyte and macrophage cell activation.

Macrophages are activated when their cognate receptors detect the presence of microbial products. In the case of cytosolic NLRs, which sense the presence of microbes and/or the damage that their infection induces, activation leads to the assembly of the inflammasome, a multiprotein complex that recruits and activates...
caspase-1 and/or caspase-11. The murine NLRP3 inflammasome senses a wide range of bacteria, pore-forming toxins, and crystaline danger signals, including alun, amyloid clusters, cholesterol, and asbestos (for a review, see reference 14). In contrast, the murine NLRP1b inflammasome is more restricted; the only characterized activator is the Bacillus anthracis lethal toxin (LT) (15). Either multimeric complex is capable of cleaving the proform of caspase-1, which is typically associated with the rapid death of macrophages, through a process known as pyroptosis (for a review, see references 1 and 2). Pyroptosis, unlike apoptosis, leads to lysis of the cell and release of its intracellular contents. Caspase-1 also cleaves the proinflammatory cytokines IL-1β and IL-18, allowing their secretion from cells (for a review, see references 1 and 2). Whether the inflammasome is activated during Toxoplasma infection, or is capable of altering disease pathogenesis, has thus far been only inferred. An association of polymorphisms in the human Nlrp1 gene with susceptibility to congenital toxoplasmosis was recently reported (16, 17). T. gondii production of cleaved IL-1β in human monocytes is dependent on both caspase-1 and the NLRP3 adaptor protein ASC (18). P2X7 receptors, which are important in ATP-mediated activation of the NLRP3 inflammasome, have also been shown to influence parasite proliferation in human and murine cells (19). IL-18, a key substrate of inflammasome-activated caspase-1, is known to enhance production of IFN-γ (20), which is a central regulator of Toxoplasma pathogenesis. Furthermore, in vivo administration of IL-1β protects mice from lethal challenge with Toxoplasma (21) and injection of antibodies against the IL-1 receptor (IL-1R) significantly attenuates the protective effect that exogenous IL-12 confers on infected SCID mice (22). Thus, we hypothesized that inflammasome activation might be an important factor mediating murine host resistance to Toxoplasma infection.

In this study, we show that murine macrophages are not susceptible to T. gondii-induced rapid pyroptosis but that NLRP3 inflammasome activation in these cells results in rapid IL-1β cleavage and release. We establish that both NLRP3 and NLRP1 are important in vivo regulators of parasite proliferation and that IL-18 signaling is required to mediate host resistance to acute toxoplasmosis. Our findings establish a role for two inflammasomes in the control of Toxoplasma infection.

RESULTS
Toxoplasma activates the inflammasome in murine macrophages without inducing cell death. Induction of protective immunity capable of controlling murine Toxoplasma infection is critically dependent on myeloid cell activation (3). The ability of this parasite to promote caspase-1 activation and the secretion of active IL-1β has recently been established in human and rat monocytes and macrophages (17, 18, 66). To determine if Toxoplasma activates the inflammasome in murine macrophages, we infected unstimulated and lipopolysaccharide (LPS)-primed bone marrow-derived macrophages (BMDMs) prepared from C57BL/6 mice with type II (Pru) parasites and measured IL-1β secretion 24 h after infection (Fig. 1A). Uninfected BMDMs did not produce measurable levels of IL-1β (Fig. 1A), whereas IL-1β was readily detected after infection with type II Toxoplasma regardless of whether the BMDMs were LPS primed or not (Fig. 1A). Western blotting of infected BMDM lysates showed the presence of mature IL-1β and showed that cleavage was dependent on caspase-1/11, since infected BMDMs from caspase-1/11-deficient mice did not possess detectable levels of cleaved IL-1β (Fig. 1B). The detection of mature IL-1β in the Toxoplasma-infected BMDMs indicated inflammasome activation, but the cells did not undergo pyroptosis over 24 h (Fig. 1C). These data support an inflammasome-mediated processing and release of mature IL-1β in the absence of pyroptosis, which have been demonstrated to occur previously (23). Interestingly, IL-18 upregulation and cleavage were not observed in Toxoplasma-infected BMDM or splenocyte lysates over a range of multiplicities of infection (MOIs) and times, and the cytokine was not released from in vitro-infected macrophages or splenocytes (data not shown).

Because IL-1β secretion was consistently dependent on MOI (data not shown), we tested whether parasite invasion was required for IL-1β secretion. Parasites pretreated with mycolic acid B, an actin-depolymerizing agent that blocks invasion but allows for secretion of microneme and rhoptry contents, attached but induced significantly smaller amounts of IL-1β secretion (Fig. 1D), indicating that macrophage inflammasome activation was invasion dependent. The small amount of IL-1β secretion by BMDMs infected by mycolic acid B-treated parasites was likely due to incomplete inhibition of invasion, as immunofluorescence microscopy performed on the same batch of treated parasites indicated that a small number had still invaded the BMDMs, as evidenced by their intracellular replication (data not shown).

IL-1β secretion correlates with strain differences in NF-κB activation. Mouse strains differ in their susceptibility to Toxoplasma depending on the infecting strain genotype; haplogroup 2 and 12 (HG2 and HG12) strains are relatively avirulent and readily establish chronic infections, whereas HG1 and HG4 to HG10 strains are acutely virulent. We sought to determine whether Toxoplasma strains differentially activate the murine macrophage inflammasome, or whether secretion of IL-1β correlated with parasite genotype and/or pathogenesis. We infected unprimed BMDMs from C57BL/6 mice with Toxoplasma tachyzoites from all 12 haplogroups for 24 h, a time point at which parasite-induced cell lysis was minimal. Cougar (HG11) and the type II, strains, with the exception of DEG, induced IL-1β secretion in unstimulated BMDMs (Fig. 1E). Inflammasome activation is often divided into a signal 1, which is the signal that leads to transcription of IL-1β, and signal 2, which is the signal that leads to the actual activation of caspase-1. Type II, but not type I or III, parasites directly activate the NF-κB transcription factor in both human and murine cells, thereby potentially providing signal 1 for the induction of IL-1β transcription. The secreted dense granule protein GRA15 determines this strain difference in NF-κB activation (24). Indeed, in murine BMDMs, type II IL-1β mRNA induction was partially dependent on type II GRA15 expression (Fig. 1F), while IL-1β secretion of unstimulated BMDMs was completely dependent on GRA15 (Fig. 1G). To determine if non-type II strains can provide signal 2, which leads to the activation of caspase-1 and subsequent cleavage and secretion of IL-1β, we prestimulated BMDMs with LPS for 2 h and subsequently infected them with different Toxoplasma strains. IL-1β was now detected in the medium with no truly apparent differences between strains (Fig. 1H). The IL-1β secreted into the medium also contained the cleaved active IL-1β (17 kDa) as determined by Western blot analysis (see Fig. S2 in the supplemental material).

Toxoplasma activation of the murine inflammasome in BMDMs is dependent on caspase-1/11 and NLRP3. To determine the components necessary for IL-1β secretion, we infected...
**FIG 1** *Toxoplasma* activates the inflammasome in C57BL/6 and 129S BMDMs. BMDMs were primed with 100 ng/ml LPS or left unstimulated for 2 h and subsequently infected with type II parasites (Pru; average MOI, 1) for 24 h. (A) Quantification of IL-1β in supernatants was performed using ELISA. (B) IL-1β cleavage was monitored by Western blotting of cell lysates from C57BL/6NTac or caspase-1/11−/− BMDMs that were infected with type II parasites (Pru; MOI, 0.8) for 24 h. The positions of both pro-IL-1β (37 kDa) and cleaved IL-1β (17 kDa) are indicated. (C) Cell viability of infected cells in panel A was determined at different time points using an MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay. Panels A and C are averages of three experiments. Error bars, ± standard deviations. (D) BMDMs were primed with LPS for 2 h and infected for 24 h with type I parasites (RH) that were pretreated with dimethyl sulfoxide vehicle or mycalolide B (3 μM) for 20 min. IL-1β was measured using ELISA. Data are averages of 2 experiments. Error bars, ± standard deviations. (E) C57BL/6 BMDMs were infected with the indicated strains for 24 h. IL-1β was measured using ELISA. Data are the averages of at
immortalized macrophages that lacked caspase-1 and -11 and showed that IL-1β secretion was completely eliminated, as expected (Fig. 1I). To determine the inflammasome components necessary for IL-1β secretion, we infected BMDMs from C57BL/6 mice that lacked Nlrp1b, Nlrp3, or both Nlrp1b and Nlrp3, or the inflammasome adaptor ASC. We found IL-1β secretion by primed BMDMs upon *Toxoplasma* type I infection to be mostly dependent on ASC and the NLRP3 inflammasome (Fig. 1J). Similar results were obtained after type II infection (see Fig. S3 in the supplemental material). The greatly reduced amount of cleaved active IL-1β in the supernatant of Nlrp3-deficient *Toxoplasma*-infected BMDMs compared to the amount present in the supernatant of wild-type (WT) or Nlrp1b-deficient infected BMDMs confirmed the importance of the NLRP3 inflammasome in *Toxoplasma*-mediated inflammasome activation in *vivo* (Fig. 1K). Thus, *Toxoplasma* induction of IL-1β secretion by murine BMDMs is highly dependent on the NLRP3 inflammasome and requires caspase-1 activation.

Inflammasome-mediated BMDM death and cytokine processing are independent of Nlrp1a and Nlrp1b alleles. Despite the activation of caspase-1 in *Toxoplasma*-infected cells, we did not observe any macrophage pyroptosis. Previous reports have shown that five polymorphic Nlrp1b alleles exist among inbred mice which control sensitivity to anthrax LT-induced pyroptosis (15). To test if the >100-amino-acid (aa) differences in Nlrp1b between C57BL/6J and 129S mice were the basis for resistance to parasite-induced pyroptosis, we compared BMDMs from the two strains. We observed no difference in cell viability between the C57BL/6J and 129S BMDMs (Fig. 1L). Thus, consistent with a major role for NLRP3 inflammasome activation, BMDMs from either 129S or C57BL/6 mice produced active IL-1β (Fig. 1M and N) without associated pyroptosis upon type I or II *Toxoplasma* strain infection. Furthermore, the fact that 129S BMDMs do not express the highly conserved NLRP1a protein (25) and are caspase-11 deficient (26) but present a robust IL-1β response also eliminated a role for NLRP1a and caspase-11 in cytotoxic matura-

Murene to *Toxoplasma* infection is controlled by caspase-1/11-dependent inflammasome activation. Whether inflammasome activation is important to murine resistance to infection *in vivo* has not yet been established. We infected mice deleted for the caspase-1/11 genes with 10,000 type II 76k green fluorescent protein-luciferase (GFP-LUC) tachyzoites intraperitoneally (i.p.) and tested for susceptibility to acute infection by monitoring mean survival time (MST), parasite growth, dissemination, and the production of IL-1β and IL-18. In the absence of caspase-1/11 proteins, mice had a 10- to 20-fold-higher parasite load (Fig. 2A and B) and were highly susceptible to acute infection (Fig. 2C). In contrast, the majority of C57BL/6NTac control mice survived acute infection and established chronic infections (Fig. 2C). Surprisingly, serum levels of systemic IL-1β never exceeded 10 pg/ml on day 5 (Fig. 2D, graph on left) or day 9 (data not shown) for either mouse strain. IL-18 levels, however, were significantly higher following infection, ranging from 0.5 to 2.0 ng/ml in C57BL/6NTac mice on day 5 (Fig. 2D), to strikingly high levels exceeding 10 ng/ml by day 9, compared to <200 pg/ml in caspase-1/11-deficient mice (Fig. 2D) or uninfected controls (data not shown).

ASC and NLRP3 inflammasome activation controls *Toxoplasma* proliferation and host resistance. We next investigated the role of ASC in murine susceptibility to *Toxoplasma* infection, since this adaptor protein is required to mediate the activation of multiple inflammasomes (27). If inflammasome activation controls *Toxoplasma* resistance, we hypothesized that mice rendered deficient in this protein will be more susceptible to acute infection. Asc-deficient mice consistently had ~20-fold or greater parasite loads at days 5 to 7 postinfection (Fig. 3A and B) and generally succumbed to infection by days 8 to 10 (Fig. 3C), in contrast to wild-type control mice, the majority of which survived acute infection at day 20 (Fig. 3C). The Asc-deficient mice likewise failed to induce detectable levels of systemic IL-18 (Fig. 3D) or IL-1β (data not shown) during acute infection.

To determine whether the NLRP3 inflammasome sensor is sufficient to confer this murine resistance to the *Toxoplasma* phenotype, Nlrp3<sup>−/−</sup> mice on the C57BL/6J background were infected intraperitoneally with 10,000 76k GFP-LUC tachyzoites. Nlrp3<sup>−/−</sup> mice were more susceptible than their wild-type (WT) controls and possessed 10-fold or higher parasite burdens at days 5 to 7, and the majority of mice died by day 10 postinfection (Fig. 3C). These infected mice produced intermediate levels of systemic IL-18 significantly greater than those of the Asc-deficient mice but not equivalent to those of the WT (Fig. 3D). They did not produce measurable levels of IL-1β (data not shown), similar to what was observed with all infections of WT mice (Fig. 2D and data not shown). Infection with another type II strain (Pru GFP-LUC) produced similar results (data not shown), indicating that the phenotype was not attributable to an anomalous *Toxoplasma* clone-specific effect or the genome integration site of the GFP.

Figure Legend Continued
LUC gene, as both type II strains activated the inflammasome in vivo. These results indicate that murine resistance to acute infection with *Toxoplasma* is highly dependent on the activation of the NLRP3 inflammasome. NLRP1 inflammasome activation also controls *Toxoplasma* proliferation and host resistance. Because the infected Nlrp3-deficient mice still produced IL-18 at levels higher than those of Asc-deficient mice, we hypothesized that more than one inflammasome is activated in vivo to produce IL-18 during *Toxoplasma* infection. To test this prediction, we infected mice deficient at the Nlrp1 locus encompassing Nlrp1abc with 10,000 76K GFP-LUC tachyzoites to determine if NLRP1 activation contributes to murine resistance during *Toxoplasma* infection. Nlrp1abc-deficient mice had only 3- to 5-fold-higher parasite loads than did WT mice across days 5 to 7 (Fig. 4B). Nlrp1abc-/- mice also died acutely, succumbing to infection by days 16 and 22 (Fig. 4C). The delayed MST kinetics was consistent with the decreased parasite burden in comparison to the Nlrp3-deficient mice. Nlrp1abc-deficient mice produced intermediate levels of systemic IL-18, significantly greater than those of the Asc-deficient mice but not equivalent to those of the WT (Fig. 4D). No measurable levels of circulating IL-1β were found on day 5 or 9 after infection in these mice or their WT controls (data not shown).

Mice deficient in signaling and secretion of IL-18 are highly susceptible to *Toxoplasma* infection. Although no systemic IL-1β was detectable in vivo, infection of NLRP3-deficient BMDMs showed markedly diminished levels of IL-1β (Fig. 1). To test if IL-1β possesses a biologically important role locally and is capable of influencing murine resistance, we infected IL-1R-deficient mice with 10,000 76K GFP-LUC tachyzoites. All IL-1R-deficient mice succumbed to infection but with a delayed kinetics compared to ASC-, caspase-1/11-, and Nlrp3-deficient mice (Fig. 5C). These mice supported higher parasite loads and had intermediate levels of IL-18 in their serum compared to WT C57BL6/J mice (Fig. 5A, B, and D), indicating that despite the absence of measurable IL-1β in circulation, IL-1 signaling does play a contributing role in the protection against murine toxoplasmosis.

Intriguingly, the level of IL-18 in the circulation of infected WT mice correlated with decreased parasite burden and increased survival. We hypothesized that inflammasome activation and the production of high systemic IL-18 might play an important role in the relative resistance of WT mice. To test our hypothesis, we...
infected IL-18\(^{-/-}\) and IL-18R\(^{-/-}\) mice. Both types of mice were highly susceptible to acute *Toxoplasma* infection and consistently had 20- to >100-fold-increased parasite loads at days 5 to 7 postinfection, greater than that found in the Asc\(^{-/-}\) mice (Fig. 5A and B). These mice typically succumbed to infection by day 8 or 9 (Fig. 5C), suggesting that the presence of IL-18 is protective in C57BL/6 mice. These data indicate that the production and secretion of activated IL-18 are associated with controlling parasite proliferation and murine resistance to acute toxoplasmosis.

**Discussion**

Generation of a robust innate immune response is required to orchestrate murine resistance against the intracellular pathogen *T. gondii*, as well as a wide spectrum of other pathogenic agents (for a review, see reference 3). Resistance to *Toxoplasma* infection is critically dependent on the TLR-associated adaptor protein MyD88 and induction of IL-12, IFN-\(\gamma\), and the synthesis of nitric oxide (NO). In this study, we show that *in vivo* generation of host protective immunity against *Toxoplasma* is also highly dependent on the inflammasome sensors NLRP1 and NLRP3 and the secretion of the caspase-1-dependent proinflammatory cytokine IL-18. Infection of mice deficient in NLRP3, NLRP1abc, caspase-1/11, or the inflammasome adaptor protein ASC led to decreased levels of circulating IL-18, increased parasite replication, and death. Using mice deficient in IL-18 and IL-18R, we show that this cytokine plays an important role in limiting parasite replication to promote murine survival.

IL-18, like IL-1\(\beta\), has been extensively linked to both protective immune responses and disease induction. IL-18 mediates enhancement of innate resistance to acute toxoplasmosis by triggering IFN-\(\gamma\) induction in immune cells, especially T and NK cells, and works in synergy with IL-12. It has previously been used as a protective treatment (28, 29), and IL-18 depletion by antibodies significantly alters murine susceptibility upon infection with lethal doses of *Toxoplasma* (30). In fact, IL-18 was at one time known as “IFN-\(\gamma\)-inducing factor” (31). The inactive pro-IL-18 form is constitutively expressed in a wide range of cell types (32) but requires processing by caspase-1 to promote its secretion, as
evidenced by the drastically depleted levels of IL-18 during infection of caspase-1/11−/− mice (Fig. 2D), and promote the induction of IFN-γ production in vivo (33, 34). Interestingly, Asc−/− deficient mice produced even less circulating IL-18, indicating that other factors such as caspase-8 (35) may contribute to IL-18 processing.

The role of IFN-γ in resistance to Toxoplasma is extensively documented (for a review, see references 3 and 4). IFN-γ activates cellular pathways that promote resistance to toxoplasmosis through multiple mechanisms, including activation of the interferon-inducible GTPases (IRG-GTPases) (36, 37) and NO regulation (9), processes certainly dependent on induction of IFN-γ by IL-18 produced following NLR inflammasome activation. However, IL-18 has also been linked to pathology during infection with type 1 strains of Toxoplasma, and IL-18 depletion resulted in enhanced survival by limiting the propathologic immune response that these virulent strains induce (30, 38). Hence, the balance between the protective and pathological roles of IL-18 is likely highly dependent on mouse genetics, Toxoplasma strain differences, challenge doses, routes of infection, and rates of disease progression. Previous work using a low-dose type II (PTG) infection in caspase-1-deficient mice (now known to be caspase-1/11 deficient) concluded that these mice were not altered in Toxoplasma susceptibility relative to wild-type control mice (39). However, this study was performed with a parasite dose that does not typically induce measurable levels of systemic IL-18 (30), and the mice used had a mixed 129/B6 background, which itself may influence pathogenesis. Our results, using mice sufficiently backcrossed onto a C57BL/6NTac background and a parasite inoculum that induces systemic IL-18, show a role for caspase-1 and IL-18 in murine resistance. IL-18 concentrations are known to vary through the course of infection and are clearly dependent on the parasite strain and inoculum used (30, 38). Our results suggest that this cytokine plays a pivotal role in mediating acute toxoplasmosis, with the cytokine playing an important early role in the control of parasite replication (Fig. 5B). How exactly IL-18 mediates this protection requires further studies. Later in infection, however, high levels of IL-18 have previously been shown to cause
dysregulated induction of propathologic cytokine levels that contribute to lethality in high-dose, virulent infections (30, 38).

The recruitment of inflammatory monocytes to sites of infection is essential to control parasite growth and dissemination in murine models of toxoplasmosis (12, 13). In rats, control of parasite proliferation and dissemination in vivo is controlled by the Toxo1 locus (40). Our recent work showed that macrophages from Toxoplasma-resistant rat strains (e.g., LEW and SHR) undergo pyroptosis in response to inflammasome activation induced by parasite infection, and this rapid cell death is sufficient to limit parasite replication and promote sterile cure (66). In previous work by Miao et al., caspase-1-induced pyroptotic cell death was also identified as an innate immune mechanism to protect against intracellular pathogen infection (41). In their study, the authors used a panel of mouse strains deficient in IL-1β, IL-18, IL-1βR, or various combinations of those to show a dispensable role for IL-1β and IL-18 in the clearance of Salmonella enterica serovar Typhimurium that expresses flagellin, suggesting that innate control of bacterial infection is occurring by pyroptosis, without a requirement to induce an overt inflammatory response. In this study, we show that in vitro Toxoplasma infection of murine bone marrow-derived macrophages primarily activates the NLRP3 inflammasome, resulting in the rapid production and cleavage of IL-1β, but does not induce pyroptosis. Interestingly, although Toxoplasma-infected macrophages showed efficient caspase-1/11-dependent IL-1β cleavage and secretion, these cells did not upregulate, cleave, or secrete their preexisting pools of IL-18. Furthermore, splenocytes also did not show any IL-18 cleavage following infection. Paradoxically, significant concentrations of IL-1β were not detected following infection in any mouse strain, whereas high levels of IL-18 were found in serum in all infection studies that we performed with different Toxoplasma strains. Because activation of the murine inflammasome does not affect Toxoplasma growth in macrophages (data not shown) and does not induce pyroptosis, our results suggest that IL-18 activation and not pyroptosis is the genetic basis for in vivo inflammasome-mediated control of parasite proliferation. Although the in vivo cellular source for this inflammasome-generated IL-18 is not known, it is likely of nonmyeloid origin, and bone marrow chimera studies should be performed to address this question.

FIG 5 Parasite load, survival, and systemic IL-18 levels in IL-18- and IL-18R-knockout mice. (A) Bioluminescence imaging of 76K GFP-LUC-infected mice (various strains, 10,000 tachyzoites, i.p. route) on days 4 to 7 following infection is shown. Images shown are 2 to 3 representative mice from 3 to 6 mice/group. The experiment shown is one of 2 IL-1β, 4 IL-18, or 4 IL-18R independent experiments. (B) P values (t test) comparing luciferase activity for each knockout strain to C57BL/6J are <0.05. (C) Aggregate survival curve of IL-1R (n = 9), IL-18 (n = 19), and IL-18R (n = 13)-knockout mice compared with WT C57BL/6J control mice (n = 13). (D) IL-18 measurements in serum of deficient mice on day 5 after infection. No detectable levels of IL-1β were detected in circulation.
results also suggest that NLRP1-mediated events may be more important in vivo and that activation of NLRP1 may likewise occur in cells other than macrophages.

The role of inflammasome activation in the pathogenesis of Toxoplasma infection in human infections has recently been suggested (16, 17). Polymorphisms in the human NLRP1 gene are associated with susceptibility to congenital toxoplasmosis, and NLRP1 contributes to controlling parasite growth in human monocytes. A recent study in human macrophages provided compelling evidence that the inflammasome components ASC and caspase-1 regulate the release of IL-1β and that the type II allele of the parasite dense granule protein GRA15, which activates NF-κB nuclear translocation, is necessary for maximal induction of this cytokine (18). Indeed, our in vitro infection data show that Toxoplasma murine inflammasome-mediated secretion of IL-1β is strain dependent and that only parasites expressing the GRA15 type II allele, which directly activates NF-κB, were able to induce secretion of IL-1β in unprimed BMDMs (Fig. 1). While the relative and contributing roles of IL-1β compared to IL-18 remain to be determined in the control of acute toxoplasmosis, our preliminary studies using IL-1 receptor-knockout mice on a mixed background argue that IL-1β plays a less significant role in the control of parasite infection than it does in IL-18 or IL-18R knockouts (Fig. 5) In vivo administration of IL-1β in LPS-primed caspase-1/11-deficient mice has previously been shown to increase IL-6 (34), so it is conceivable that IL-1β functions locally to induce increased levels of IL-6 capable of altering inflammation-induced changes in myeloid output that impact Toxoplasma pathogenesis (42).

Of the two NLR inflammasomes activated, we found that murine resistance to acute infection was principally dependent on activation of the NLRP3 receptor both in vitro (Fig. 1) and in vivo (Fig. 3). Several reports have linked P2X(7) receptor, a potent activator of the NLRP3 inflammasome, with control of acute toxoplasmosis (16, 19, 43, 44). How and in what cell type Toxoplasma activates the murine NLRP3 inflammasome or why its activation does not lead to rapid macrophage death or IL-18 processing is enigmatic. Regulators of the NLRP3 inflammasome include ATP, the guanylate-binding protein 5 (GBP5), cellular stresses that alter calcium and potassium concentrations, redox status, and the unfolded protein response (UPR) (for a review, see reference 45). Importantly, Toxoplasma encodes a variety of virulence effector proteins that specifically inactivate the host endoplasmic reticulum (ER)-bound transcription factor ATF6β and induction of the UPR during ER stress (46), affect the recruitment of 65-kDa guanylate-binding proteins (GBP’s) (47, 48), or alter calcium and potassium efflux to signal Toxoplasma egress (49), perhaps indicating that the parasite has specifically evolved effector proteins to minimize NLR inflammasome activation to alter its pathogenesis.

Our work also identified Toxoplasma as the second pathogen, after B. anthracis, whose pathogenesis is altered by expression of the murine NLRP1 inflammasome (15). We show that the Nlrp1 locus is capable of regulating parasite proliferation in vivo, with Nlrp1 knockout mice possessing significantly higher parasite burdens following Toxoplasma infection. Although the majority of NLRP1-deficient mice died acutely (Fig. 4), they were, however, less susceptible to infection than were caspase-1/11-, Asc-, Nlrp3-, IL-18-, or IL-18R-deficient mice in the same genetic background and possessed only 5- to 10-fold-higher parasite loads than in WT infections. How Toxoplasma activates the NLRP1 inflammasome is unclear. Activation of rodent NLRP1 inflammasomes by the B. anthracis lethal toxin (LT) occurs via proteolytic cleavage at a specific consensus sequence in the polymorphic N terminus of NLRP1 (50, 51). In human infection, NLRP1 polymorphism variants are likewise known to alter the susceptibility to congenital toxoplasmosis (17). One logical hypothesis is that the Toxoplasma-encoded effector molecule responsible for activation of NLRP1 is, like LT, a protease. Toxoplasma secretes a wide range of proteases (52–57), and similar induction of IL-1β observed upon infection of primed BMDMs with any Toxoplasma strain suggests that the putative protease, or factor responsible for activation of NLRP1, is not likely to be Toxoplasma strain specific or is at least conserved among the majority of strains. Alternatively, polymorphisms in Nlrp1 could affect the interaction with a different host “sensor” protein that serves as the adaptor for assembly and activation of the NLRP1 inflammasome, as has been previously described for the NLRC4/NAIP5/NAIP6 inflammasome recognition of flagellin (58, 59).

In summary, we establish that both NLRP3 and NLRP1 are important in vivo regulators of Toxoplasma proliferation and that IL-18 signaling is required to mediate host resistance to acute toxoplasmosis. Our findings also indicate that innate resistance to acute toxoplasmosis is dependent on the activation of both TLR and NLR sensors that cooperate to detect the presence of pathogen products or the danger signals that they induce during active infection. The identification of the Toxoplasma factor that mediates NLR inflammasome activation may contribute new insight into the development of therapeutic options to combat this important human pathogen.

MATERIALS AND METHODS

Ethics statement. All animal experiments were performed in strict accordance with guidelines from the NIH and the Animal Welfare Act, under protocols approved by the Animal Care and Use Committee of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (protocols LPD-8E and LPD-22E), and the MIT Committee on Animal Care (assurance number A-3125-01).

Material. Ultrapure LPS was purchased from Calbiochem/EMD Biosciences (San Diego, CA). Luciferin was purchased from Caliper Life Sciences (Hopkinton, MA). Nigericin was purchased from Invivogen (San Diego, CA). Mycaloilide B was purchased from Wako (Richmond, VA).

Mice and NLRP1 expression status-based nomenclature. IL-18- and IL-18 receptor (IL-18R)-knockout mice on the C57BL/6J background (>10 backcrosses) and IL-1R-deficient mice on a partially backcrossed 129 × C57BL/6J background were obtained from Jackson Laboratories (Bar Harbor, ME). Caspase-1-knockout mice have been previously described (60) and were backcrossed to C57BL/6NTac mice for 10 generations. These caspase-1-knockout mice are also deficient in caspase-11 (26). Mice deleted for all three Nlrp1 genes in the murine Nlrp1abc locus (C57BL/NTac background), as well as those deleted only for Nlrp1b (C57BL/6J background), have been previously described (61, 62). Mice deleted at Nlrp3 (C57BL/6J background) (63) and Asc (C57BL/6J background) (60) have been previously described.

Parasites. Tachyzoites from luciferase-expressing type I (RH) and type II (76K or Prugniaud) T. gondii parasites were used for all studies. The following strains (haplogroup/type in parentheses) were used in a survey of effects on murine BMDMs: GTI I (ME49 II), DEG II (CEP III), VEG (III), CASTLELS (IV), MAS (IV), GUY-KOE (V), GUY-MAT (V), RUB (V), BOF (VI), GPHT (VI), CAST (VII), TgCATB5r (VIII), F89 (IX), GUY-DOS (X), VAND (X), Cougar (XI), B41 (XII), B73 (XII), RAY (XII), and WTD3 (XII). The generation of luciferase-expressing parasites using the plasmid pHFR-Luc-GFP gene cassette has been described previously (64). To construct the RH, Prugniaud, and 76K GFP-LUC strains, pHFR-Luc-GFP was linearized with NotI, parasites were electroporated,
and those with stable GFP expression were isolated by fluorescence-activated cell sorting and cloned by limiting dilution. Generation of Pru GRA15-knockout (KO) parasites has been previously described (24). All parasite strains were routinely passaged in vitro in monolayers of human foreskin fibroblasts (HFFs) at 37°C in the presence of 5% CO2 and quantified by hemocytometer counts prior to infection studies. In some experiments, mycolate B (3 μM, 20 min) was used to pretreat isolated parasites prior to washing in phosphate-buffered saline (PBS) (3×) before infections.

Cell culture. Bone marrow-derived macrophages (BMDMs) were cultured in complete Dulbecco’s modified Eagle’s medium (DMEM) with 20% L929 cell culture supernatant for 7 days. L929 mouse fibroblast cells were grown in DMEM supplemented with 10% fetal bovine serum, 10 mM HEPES, and 50 μg/ml gentamicin (all obtained from Invitrogen, Carlsbad, CA) at 37°C in 5% CO2. BMDMs with or without LPS priming (0.1 μg/ml, 2 h) were infected with Toxoplasma at various multiplicities of infection (MOIs), and cell viability was assessed at 24 h using the CellTiter 96 AQueous One Solution cell proliferation assay (Promega, Madison, WI). Culture supernatants were removed for cytokine measurements by enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN) or Western blotting, following concentration using Amicon filters (3,000-molecular-weight cutoff) (Millipore, Billerica, MA) or Spin-X UF 500 concentrators (5,000-molecular-weight cutoff) (Corning, United Kingdom). For Western blots, anti-mouse IL-1β (Abcam, Cambridge, MA) or anti-caspase-1 antibody (Abcam, Cambridge, MA) was used as the primary antibody. Secondary antibodies were from Jackson Immunoresearch (West Grove, PA). Immune-activated cell sorting and cloned by limiting dilution. Generation of Pru infections.

Microarray analysis. Microarray analyses were performed as previously described (65).

Mouse infections. Mice (male and female, 8 to 12 weeks old) were infected intraperitoneally (i.p.) with either 10,000 (76K) or 1,200 (Pru) type II tachyzoites diluted in 400 μl of phosphate-buffered saline. Mice were imaged on successive days (typically days 4 to 9) postinfection, and parasite burden was quantified by firefly luciferase activity using an IVIS BLI system from Caliper Life Sciences. Mice were injected i.p. with 3 mg of α-luciferin substrate (prepared in 200 μl of PBS) and imaged for 5 min to detect photons emitted, as previously described (64). Mice were bleed by tail vein at day 5 and/or day 9 after infection. Blood collection was performed in either serum collector or Microtainer EDTA tubes (Sarstedt, Minneapolis, MN). Resultant Microbial Biodiversity.

ACKNOWLEDGMENTS

This work was supported in part by the Intramural Research Program of the NIH and NIAID (M.E.G., S.H.L., and A.S.). G.G. was supported by a research fellowship award from the Crohn’s & Colitis Foundation of America (CCFA) and is a CCFA Helmsley Scholar. K.M.C. was supported by NIH grant AI104170. J.P.S. was supported by R01-AI080861 and a Pew Scholar in the Biomedical Sciences Award. M.E.G. is a scholar of the Canadian Institute for Advanced Research (CIFAR) Program for Integrated Microbial Biodiversity.

REFERENCES

1. Lamkanfi M, Dixit VM. 2012. Inflammasomes and their roles in health and disease. Annu. Rev. Cell Dev. Biol. 28:137–161. http://dx.doi.org/10.1146/annurev-cellbio-101011-155745.
2. Song DH, Lee JO. 2012. Sensing of microbial molecular patterns by Toll-like receptors. Immunol. Rev. 250:216–229. http://dx.doi.org/10.1111/j.1600-065X.2012.01167.x.
3. Hunter CA, Sibley LD. 2012. Modulation of innate immunity by Toxoplasma gondii virulence effectors. Nat. Rev. Microbiol. 10:766–778. http://dx.doi.org/10.1038/nrmicro2858.
4. Melo MB, Jensen KD, Saeij JP. 2011. Toxoplasma gondii effectors are master regulators of the inflammatory response. Trends Parasitol. 27: 487–495. http://dx.doi.org/10.1016/j.pt.2011.08.001.
5. Khan IA, Schwartzman JD, Matsuura T, Kasper LH. 1997. A dichotomous role for nitric oxide during acute Toxoplasma gondii infection in mice. Proc. Natl. Acad. Sci. U. S. A. 94:13955–13960. http://dx.doi.org/10.1073/pnas.94.25.13955.
6. LaRosa DF, Stumbofer JS, Gelman AE, Rahman AH, Taylor DK, Hunter CA, Turka LA. 2008. T cell expression of MyD88 is required for resistance to Toxoplasma gondii. Proc. Natl. Acad. Sci. U. S. A. 105:3855–3860. http://dx.doi.org/10.1073/pnas.0706663105.
7. Scanga CA, Aliberti J, Jankovic D, Tilloy F, Bennouna S, Denkers EY, Neote K, Tovar-Spencer R, Arpin A, Aliberti J. 2008. Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J. Immunol. 168:5997–6001.
8. Scharton-Kersten TM, Wynn TA, Denkers EY, Bala S, Grunvald E, Zolzer M, Saeij JP. 2008. In the absence of endogenous IFN-γ, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection. J. Immunol. 157: 4045–4054.
9. Scharton-Kersten TM, Yap G, Magram J, Sher A. 1997. Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondii. J. Exp. Med. 185: 1261–1273. http://dx.doi.org/10.1084/jem.185.7.1261.
10. Sher A, Collazo C, Scanga C, Jankovic D, Yap G, Aliberti J. 2003. Induction and regulation of IL-12-dependent host resistance to Toxoplasma gondii. Immunol. Rev. 257:521–528. http://dx.doi.org/10.1111/j.1600-0830.2003.3702335.x.
11. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. 1988. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 240:516–518. http://dx.doi.org/10.1126/science.3128869.
12. Dunay IR, Damatta RA, Fux B, Presti R, Greco S, Colonna M, Sibley LD. 2008. Gr(1+) inflammatory monocytes are required for mucosal resistance to the pathogen Toxoplasma gondii. Immunol. 29:306–317. http://dx.doi.org/10.1016/j.immuni.2008.05.019.
13. Robben PM, LaRegina M, Kuziel WA, Sibley LD. 2005. Recruitment of Gr-1+ monocytes is essential for control of acute toxoplasmosis. J. Exp. Med. 201:1761–1769. http://dx.doi.org/10.1084/jem.20050054.
14. Martinon F, Mayor A, Tschopp J. 2009. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27:229–265. http://dx.doi.org/10.1146/annurev.immunol.021108.132656.
15. Bowden ED, Dietrich WE. 2006. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet. 38:240–244. http://dx.doi.org/10.1038/ng1724.
16. Jamieson SE, Peixoto-Rangel AL, Hargrave AG, Roubaix LA, Mui EJ, Boulter NR, Miller EN, Fuller SJ, Wiley JS, Castellucci L, Boyer K, Peixe RG, Kirišits MJ, Elias LS, Coyne JJ, Correa-Oliveira R, Sautter M, Smith NC, Lees MP, Swisher CN, Heydemann P, Noble AG, Patel D, Bardo D, Burrowses D, McLone D, Roizen N, Withers S, Bahia-Oliveira LM, McLeod R, Blackwell JM. 2010. Evidence for associations between the purinergic receptor P2X(7) (P2RX7) and toxoplasmosis. Toxoplasmosis. 11:374–383. http://dx.doi.org/10.1016/j.toxcon.2010.03.1017.
17. Witola WH, Mui E, Hargrave A, Liu S, Hylpolite M, Montpetit A, Cavallees P, Bisanz C, Cesbron-Delawu MF, Fournié GJ, McLeod R. 2011.NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells. Infect. Immun. 79:756–766. http://dx.doi.org/10.1128/IAI.00898-10.
18. Gov L, Karimzadeh A, Ueno N, Lodno MB. 2013. Human innate immunity to Toxoplasma gondii is mediated by host caspase-1 and ASC and parasite GRA15. mBio 4(4):e00255-13. http://dx.doi.org/10.1128/mBio.00255-13.

SUPPLEMENTAL MATERIAL
Supplemental material for this article can be found at http://mbio.asm.org/lookup/suppl/doi:10.1128/mBio.01117-13/-/DCSupplemental.
Figure S1, TIF file, 0.1 MB.
Figure S2, TIF file, 0.1 MB.
Figure S3, TIF file, 0.1 MB.

Gorfu et al.
19. Lees MP, Fuller SJ, McLeod R, Boulter NR, Miller CM, Zakrzewski JP, Warren SE, Wewers MD, Aderem A. 2011. Dysregulation of the inflammatory response to the parasite, Toxoplasma gondii. J. Exp. Med. 208:1393–1408. http://dx.doi.org/10.1084/jem.20110331.

20. Yoon DY, Reznikov LL, Kim SH, Rubinstein M. 2001. IFN-gamma overproduction and high level apoptosis are associated with high but not low virulence Toxoplasma gondii infection. J. Immunol. 166:3138–3146. http://dx.doi.org/10.4049/jimmunol.166.6.3138.

21. Hunter CA, Chizzonite R, Remington JS. 2001. IFN-gamma overproduction and high level apoptosis are associated with high but not low virulence Toxoplasma gondii infection. J. Immunol. 166:3138–3146. http://dx.doi.org/10.4049/jimmunol.166.6.3138.

22. Yoshida A, Uchida AM, Grigg M, Carruthers VB. 2001. A heritable defect in IL-12 production in mice. J. Immunol. 166:5440–5450. http://dx.doi.org/10.4049/jimmunol.166.9.5440.

23. Subra JF, Lagrange D, Calise M, Appolinaire S, Faraut T, Druet P, Saoudi A, Bessieres MH, Pipy B, Cesbron-Delauw MF, Fournié GJ. 2006. The rat Tox1 locus directs toxoplasmosis outcome and controls parasite proliferation and spreading by macrophage-dependent mechanisms. Proc. Natl. Acad. Sci. U. S. A. 103:744–749. http://dx.doi.org/10.1073/pnas.0506643103.

24. Miller CM, Zakrzewski AM, Leppla SH, Moayeri M. 2002. The rat Toxo1 locus directs toxoplasmosis outcome and controls parasite proliferation and spreading by macrophage-dependent mechanisms. Proc. Natl. Acad. Sci. U. S. A. 103:744–749. http://dx.doi.org/10.1073/pnas.0506643103.

25. mashburn AV, Turner RM, Gage PJ, DebRoy S, Mutha SS, Laurencin CT, Slaughter SB. 2010. Analysis of secreted proteases of Toxoplasma gondii. PLoS Pathog. 6:e1000942. http://dx.doi.org/10.1371/journal.ppat.1000942.

26. Fruth IA, Arrizabalaga G. 2007. Toxoplasma gondii: induction of egress by the potassium ionophore,nigericin. Int. J. Parasitol. 37:1559–1567. http://dx.doi.org/10.1016/j.ijpara.2007.05.010.

27. Fruth IA, Arrizabalaga G. 2007. Toxoplasma gondii: induction of egress by the potassium ionophore,nigericin. Int. J. Parasitol. 37:1559–1567. http://dx.doi.org/10.1016/j.ijpara.2007.05.010.

28. Selleck EM, Fentress SJ, Beatty WL, Degrandi D, Pfeffer K, Virgin HW. 2013. Guanylate-binding protein 1 (Gbp1) contributes to cell-autonomous immunity against Toxoplasma gondii. PLoS Pathog. 9:e1003320. http://dx.doi.org/10.1371/journal.ppat.1003320.

29. Chou DB, Sworder B, Bouladoux N, Roy CN, Uchida AM, Grigg M, Carruthers VB. 2001. A heritable defect in IL-12 production in mice. J. Immunol. 166:5440–5450. http://dx.doi.org/10.4049/jimmunol.166.6.5440.

30. Yamamoto M, Ma JS, Mueller C, Kamiyama N, Saiga H, Kubo E, Kimura T, Okamoto T, Okuyama M, Kayama H, Nagamune K, Takahima S, Matsuura Y, Soldati-Favre D, Takeda K. 2011. ATP/IFNβ is a host cellular target of the Toxoplasma gondii virulence factor ROP18. J. Exp. Med. 208:1533–1546. http://dx.doi.org/10.1084/jem.20101660.

31. Niedelmann W, Sprokholt JK, Clough B, Frickel EM, Saiei JP. 2013. Cell death of interferon-gamma stimulated human fibroblasts upon Toxoplasma gondii infection induces early parasite egress and limits parasite replication. Infect. Immun. 81:4331–4349.

32. Yoon DY, Reznikov LL, Kim SH, Rubinstein M. 2001. IFN-gamma overproduction and high level apoptosis are associated with high but not low virulence Toxoplasma gondii infection. J. Immunol. 166:3138–3146. http://dx.doi.org/10.4049/jimmunol.166.6.3138.

33. Newman ZL, Printz MP, Liu S, Crown D, Breen L, Miller-Randolph S, Santos E, Wewers MD, Aderem A. 2010. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular pathogens. Nature 467:1136–1142. http://dx.doi.org/10.1038/nri.1960.

34. Chou DB, Sworder B, Bouladoux N, Roy CN, Uchida AM, Grigg M, Carruthers VB. 2001. A heritable defect in IL-12 production in mice. J. Immunol. 166:5440–5450. http://dx.doi.org/10.4049/jimmunol.166.6.5440.

35. Mashburn AV, Turner RM, Gage PJ, DebRoy S, Mutha SS, Laurencin CT, Slaughter SB. 2010. Analysis of secreted proteases of Toxoplasma gondii. PLoS Pathog. 6:e1000942. http://dx.doi.org/10.1371/journal.ppat.1000942.

36. Fruth IA, Arrizabalaga G. 2007. Toxoplasma gondii: induction of egress by the potassium ionophore nigericin. Int. J. Parasitol. 37:1559–1567. http://dx.doi.org/10.1016/j.ijpara.2007.05.010.

37. Fruth IA, Arrizabalaga G. 2007. Toxoplasma gondii: induction of egress by the potassium ionophore nigericin. Int. J. Parasitol. 37:1559–1567. http://dx.doi.org/10.1016/j.ijpara.2007.05.010.

38. Mashburn AV, Turner RM, Gage PJ, DebRoy S, Mutha SS, Laurencin CT, Slaughter SB. 2010. Analysis of secreted proteases of Toxoplasma gondii. PLoS Pathog. 6:e1000942. http://dx.doi.org/10.1371/journal.ppat.1000942.

39. Mashburn AV, Turner RM, Gage PJ, DebRoy S, Mutha SS, Laurencin CT, Slaughter SB. 2010. Analysis of secreted proteases of Toxoplasma gondii. PLoS Pathog. 6:e1000942. http://dx.doi.org/10.1371/journal.ppat.1000942.

40. Mashburn AV, Turner RM, Gage PJ, DebRoy S, Mutha SS, Laurencin CT, Slaughter SB. 2010. Analysis of secreted proteases of Toxoplasma gondii. PLoS Pathog. 6:e1000942. http://dx.doi.org/10.1371/journal.ppat.1000942.

41. Mashburn AV, Turner RM, Gage PJ, DebRoy S, Mutha SS, Laurencin CT, Slaughter SB. 2010. Analysis of secreted proteases of Toxoplasma gondii. PLoS Pathog. 6:e1000942. http://dx.doi.org/10.1371/journal.ppat.1000942.

42. Mashburn AV, Turner RM, Gage PJ, DebRoy S, Mutha SS, Laurencin CT, Slaughter SB. 2010. Analysis of secreted proteases of Toxoplasma gondii. PLoS Pathog. 6:e1000942. http://dx.doi.org/10.1371/journal.ppat.1000942.

43. Mashburn AV, Turner RM, Gage PJ, DebRoy S, Mutha SS, Laurencin CT, Slaughter SB. 2010. Analysis of secreted proteases of Toxoplasma gondii. PLoS Pathog. 6:e1000942. http://dx.doi.org/10.1371/journal.ppat.1000942.

44. Mashburn AV, Turner RM, Gage PJ, DebRoy S, Mutha SS, Laurencin CT, Slaughter SB. 2010. Analysis of secreted proteases of Toxoplasma gondii. PLoS Pathog. 6:e1000942. http://dx.doi.org/10.1371/journal.ppat.1000942.

45. Mashburn AV, Turner RM, Gage PJ, DebRoy S, Mutha SS, Laurencin CT, Slaughter SB. 2010. Analysis of secreted proteases of Toxoplasma gondii. PLoS Pathog. 6:e1000942. http://dx.doi.org/10.1371/journal.ppat.1000942.
Adv. Exp. Med. Biol. 712:49–61. http://dx.doi.org/10.1007/978-1-4419-8414-2_4.

55. Dou Z, Coppens I, Carruthers VB. 2013. Non-canonical maturation of two papain-family proteases in Toxoplasma gondii. J. Biol. Chem. 288:3523–3534. http://dx.doi.org/10.1074/jbc.M112.443697.

56. Kim K. 2004. Role of proteases in host cell invasion by Toxoplasma gondii and other Apicomplexa. Acta Trop. 91:69–81. http://dx.doi.org/10.1016/j.actatropica.2003.11.016.

57. Shea M, Jäkle U, Liu Q, Berry C, Joiner KA, Soldati-Favre D. 2007. A family of aspartic proteases and a novel, dynamic and cell-cycle-dependent protease localization in the secretory pathway of Toxoplasma gondii. Traffic 8:1018–1034. http://dx.doi.org/10.1111/j.1600-0854.2007.00389.x.

58. Kofoid EM, Vance RE. 2011. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 477:592–595. http://dx.doi.org/10.1038/nature10394.

59. Zhao Y, Yang J, Shi J, Gong YN, Lu Q, Xu H, Liu L, Shao F. 2011. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 477:596–600. http://dx.doi.org/10.1038/nature10510.

60. Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant EP, Bertin J, Coyle AJ, Galán JE, Askennase PW, Flavell RA. 2006. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24:317–327. http://dx.doi.org/10.1016/j.immuni.2006.02.004.

61. Kovarova M, Hesker PR, Jania L, Nguyen M, Snouwaert JN, Xiang Z, Lommatschz SE, Huang MT, Ting JP, Koller BH. 2012. NLRP1-dependent pyroptosis leads to acute lung injury and morbidity in mice. J. Immunol. 189:2006–2016. http://dx.doi.org/10.4049/jimmunol.1201065.

62. Masters SL, Gerlic M, Metcalf D, Preston S, Pellegrini M, O’Donnell JA, McArthur K, Baldwin TM, Chevrier S, Nowell CJ, Gengia LH, Henley KJ, Collinge JE, Kastner DL, Feigenbaum L, Hilton DJ, Alexander WS, Kile BT, Croker BA. 2012. NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity 37:1009–1023. http://dx.doi.org/10.1016/j.immuni.2012.08.027.

63. Mariathasan S, Weiss DS, Newton K, McBride J, O’Rourke K, Roosevelt-Girman M, Lee WP, Weinrauch Y, Monack DM, Dixit VM. 2006. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440:228–232. http://dx.doi.org/10.1038/nature04515.

64. Saeij JP, Boyle JP, Grigg ME, Arrizabalaga G, Boothroyd JC. 2005. Bioluminescence imaging of Toxoplasma gondii infection in living mice reveals dramatic differences between strains. Infect. Immun. 73:695–702. http://dx.doi.org/10.1128/IAI.73.2.695-702.2005.

65. Jensen KD, Wang Y, Wojno ED, Shastri AJ, Hu K, Cornel L, Boedec E, Ong YC, Chien YH, Hunter CA, Boothroyd JC, Saeij JP. 2011. Toxoplasma polymorphic effectors determine macrophage polarization and intestinal inflammation. Cell Host Microbe 9:472–483. http://dx.doi.org/10.1016/j.chom.2011.04.015.

66. Cirelli KM, Gorfu G, Hassan MA, Printz M, Crown D, Leppla SH, Grigg ME, Saeij JP, Moayeri M. Inflammasome sensor NLRP1 controls rat macrophage susceptibility to Toxoplasma gondii. PLoS Pathog., in press.
